HAYA Therapeutics secures USD 1 billion deal with Lilly to target obesity through RNA platform
Summary
HAYA Therapeutics has announced a landmark collaboration with pharmaceutical giant Lilly, securing up to USD 1 billion in funding. The partnership aims to leverage HAYAs proprietary RNA platform to discover novel regulatory genome targets for obesity and related metabolic conditions, marking a significant step forward in the fight against these global health challenges.HAYA on stage at the TOP 100 Swiss Startup Awards Night, 2023
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected